What CBD Sellers Can and Can’t Claim: FDA Warning Letters, the FTC and a Compliance Checklist

November 18, 2026 · Licensing & Regulation

This guide is for CBD and hemp brand owners, marketers and retailers who write product pages, ads, social posts or packaging. It explains which kinds of statements have drawn FDA warning letters and FTC enforcement, why “it’s only a blog post” is not a defense, and how to review your copy before it goes live. It replaces an older HempDollars post that made health claims about CBD; this version makes none.

Key takeaways
  • FDA treats a product marketed to diagnose, treat, cure, mitigate or prevent disease as an unapproved drug, regardless of what the label calls it.
  • FDA also says CBD cannot be sold as a dietary supplement or added to food in interstate commerce, so the supplement “structure/function” route is not available for CBD.
  • The FTC requires competent and reliable scientific evidence for health claims. In its December 2020 “Operation CBDeceit” it settled with six CBD sellers over disease claims.
  • Testimonials, blog posts, influencer content and reviews count as marketing. The FTC’s consumer review rule took effect October 21, 2024.
  • Products that look like children’s snacks have drawn joint FDA and FTC warning letters.

Two agencies, two different questions

Two federal agencies police CBD marketing, and they ask different questions.

  • FDA asks what the product is. Under the Federal Food, Drug, and Cosmetic Act, a product’s legal category depends on its intended use, and intended use is shown by your claims. Say it treats a disease and FDA reads it as a drug. FDA’s cosmetics guidance says a product marketed to treat or prevent disease, or to affect the structure or function of the body, including the skin, is a drug even if it is sold as a cosmetic.
  • The FTC asks whether the advertising is truthful and supported. Under Section 5 of the FTC Act, any objective claim, stated or implied, must be backed by adequate evidence before it runs. For health claims, the FTC’s Health Products Compliance Guidance calls for competent and reliable scientific evidence, generally meaning well-designed human clinical trials.

Both agencies look at the whole presentation: product names, images, hashtags, linked articles, customer quotes you repost and metadata. A disclaimer in small print does not cancel a claim made in a headline.

What FDA warning letters target

FDA’s position on CBD has been consistent since the 2018 Farm Bill. According to FDA’s Q&A on cannabis-derived products:

  • CBD is the active ingredient in an approved prescription drug, Epidiolex, and FDA states that no other FDA-approved drug products contain CBD.
  • FDA has concluded that CBD products are excluded from the definition of a dietary supplement.
  • Introducing a food (including animal food) with added CBD or THC into interstate commerce is a prohibited act under section 301(ll).

That leaves a CBD seller with very little room. An ingestible CBD product marketed with disease claims is, in FDA’s view, an unapproved new drug. Without disease claims it is still an unlawful food or a product that does not qualify as a supplement. FDA has chosen to prioritize the first group, plus products that pose particular risks.

FDA maintains a public list of warning letters to firms marketing cannabis-derived products. As of its September 2025 update, the list ran through an August 2025 letter and included several firms whose names indicate pet products, a bakery, and a feminine care brand. Older letters, from 2015 and 2016, were published with FDA lab results showing that some products labeled as containing CBD had little or none. That is a reminder that label accuracy is also a compliance issue, not just a quality issue. For more on testing, see our guide to reading a certificate of analysis.

Products that appeal to children

In July 2023 FDA and the FTC jointly warned six companies selling edibles containing delta-8 THC in packaging that imitated well-known snack and candy brands. FDA cited violations of the FD&C Act and asked for written responses within 15 working days; the FTC demanded the companies stop marketing those products. A second round of joint letters followed in July 2024. Copycat packaging is now one of the clearest red lines in this industry.

What the FTC has done

On December 17, 2020 the FTC announced “Operation CBDeceit,” its first law enforcement sweep aimed at CBD marketing. It announced settlements with six sellers. According to the FTC, the companies had claimed CBD could treat or prevent serious diseases such as cancer, heart disease and Alzheimer’s, that it worked better than prescription pain drugs, and in some cases that their claims were scientifically proven or confirmed by the government.

The settlement terms are a useful guide to what the FTC expects:

  • Claims that a product prevents, treats or cures a disease, or is safe, need support from human clinical testing.
  • Other health claims need competent and reliable scientific evidence.
  • Five of the six companies agreed to payments, which the FTC listed individually, from $20,000 to $85,000.
  • The companies had to notify customers about the orders.

The FTC warned at the time that later violations of a final order can carry civil penalties per violation.

The FTC’s Health Products Compliance Guidance, which replaced its 1998 supplement advertising guide, adds several points that apply directly to CBD copy. Animal or test-tube studies alone are not enough to support human health claims. Hedge words like “may” or “promising” usually do not fix an unsupported claim. And a testimonial is never substantiation by itself.

Claims that create risk, with safer alternatives

The table below is illustrative. It shows the kinds of statements that have drawn enforcement and the kind of factual, product-focused copy that keeps a page on safer ground. It is not legal advice, and no wording makes an unlawful product lawful.

Risky (implies disease or drug use) Safer (factual, product-focused)
Names a disease or condition, in copy, product names, hashtags or image text Describe the product: format, size, ingredients, extraction method, flavor
Compares the product to a prescription drug Explain how it is made and tested, with a link to the batch COA
Cites studies to suggest the product treats anything State verifiable facts: cannabinoid content per serving as tested, farm origin, license status
Dosing advice tied to a health problem Neutral serving information that matches the label
“Clinically proven,” “doctor recommended,” “FDA approved” No implied endorsements you cannot document; never imply FDA approval
Pet copy about treating a condition in animals Product facts only; see our animal feed and bedding guide for FDA’s animal food position

Watch the indirect routes too. The FTC’s guidance treats implied claims the same as express ones, and FDA reads intended use from your marketing as a whole. Linking product pages to articles about a disease, reposting customer comments that name conditions, or bidding on search keywords for a condition can all suggest the same intended use a direct claim would.

Reviews, testimonials and influencers

Under the FTC’s Health Products Compliance Guidance, you are responsible for misleading testimonials you use. If customers’ experiences are not typical, a generic “results not typical” note is not enough. Paid influencers and anyone with a material connection to the brand must disclose that connection clearly.

The FTC’s rule on consumer reviews and testimonials, announced August 14, 2024 and in effect since October 21, 2024, adds civil penalty exposure. Among other things, it bans:

  • Fake reviews, including AI-generated reviews and reviews by people with no real experience of the product.
  • Paying or rewarding customers for reviews that express a particular sentiment.
  • Undisclosed insider reviews by officers, managers or certain relatives.
  • Company-controlled “independent” review sites.
  • Suppressing negative reviews through threats or groundless legal action.
  • Buying fake followers or views to misrepresent influence.

In December 2025 the FTC sent warning letters to ten companies about possible violations of the rule. For CBD brands, the practical rule is simple: moderate reviews for disease claims, never write or buy them, and keep records of any incentives you offer.

A pre-publication compliance checklist

  1. Classify the product. Is it a seed food, a topical, an ingestible CBD product, or a pet product? Each carries different federal and state risk. Our hemp food and FDA guide explains the seed-versus-CBD line.
  2. Check the hemp definition status. As of November 18, 2026, CRS reports that most of P.L. 119-37’s changes, including the 0.4 mg total THC per container cap, take effect December 11, 2026, while the exclusion of cannabinoids the plant cannot naturally produce took effect November 12, 2026. See the new federal hemp definition explained.
  3. Scrub disease language from product names, descriptions, image text, alt text, metadata, hashtags, ads and email.
  4. Match label to lab. Content claims must match a current COA for the batch being sold.
  5. Audit user content and affiliates. Remove reposted testimonials with disease claims and set written rules for affiliates and influencers.
  6. Review packaging for child appeal. No designs that imitate snacks or candy brands.
  7. Check state rules and platform policies. Many states regulate labeling, age limits and product types; see our state hemp laws guide. Ad platforms have their own rules, covered in selling hemp products online.
  8. Keep a claims file. For every objective claim, file the evidence that supports it before publishing.

Rules change; confirm with your state department of agriculture and USDA AMS before acting. This article is for education only and is not investment, legal, or tax advice.

Frequently asked questions

Can I use a structure/function claim for a CBD product like supplement brands do?

Structure/function claims are a dietary supplement concept. FDA has concluded that CBD products are excluded from the dietary supplement definition, so that framework does not provide a safe harbor for CBD. The FTC’s substantiation requirement would apply to such a claim anyway.

Does a disclaimer like “not evaluated by FDA” protect me?

No. The FTC’s guidance says a disclaimer does not cure a deceptive health claim, and FDA judges intended use from all of your marketing. A disclaimer cannot offset a disease claim elsewhere on the page.

Are blog posts and social media covered?

Yes. Both agencies look at websites, social media and linked content. This article replaces an older HempDollars post because health-claim content on a seller-affiliated site is exactly the kind of material regulators review.

What happens after an FDA warning letter?

FDA typically asks for a written response, often within 15 working days, explaining how the firm will correct the violations. FDA states that failure to act can lead to legal action such as seizure or injunction.

Do these rules apply to topical CBD?

Yes. A topical marketed to treat a condition or to change the structure or function of the skin is a drug under FDA’s cosmetics guidance. FTC substantiation rules apply to topical advertising too.

Sources

  1. U.S. FDA, FDA Regulation of Cannabis and Cannabis-Derived Products, Including CBD: Q&A (updated 2024)
  2. U.S. FDA, Warning Letters for Cannabis-Derived Products (updated 2025)
  3. U.S. FDA, FDA, FTC Warn Six Companies for Illegally Selling Copycat Food Products Containing Delta-8 THC (2023)
  4. FTC, FTC and FDA Send Second Set of Cease-and-Desist Letters to Companies Selling Delta-8 THC Products (2024)
  5. U.S. FDA, Cosmetics Labeling Claims
  6. FTC, FTC Announces Crackdown on Deceptively Marketed CBD Products (2020)
  7. FTC, Health Products Compliance Guidance (2022)
  8. FTC, Federal Trade Commission Announces Final Rule Banning Fake Reviews and Testimonials (2024)
  9. FTC, FTC Warns 10 Companies About Possible Violations of the Agency’s New Consumer Review Rule (2025)
  10. Congressional Research Service, Delay in Changes to Hemp Definition, LSB11496 (October 2026)

Figures last checked: November 18, 2026.

Originally posted 2020-06-23 21:52:38. Republished by Blog Post Promoter

🌱 Finished reading? You earned 5 seeds.

Every article you read to the end earns seeds in Hemp Empire, our free hemp farming tycoon game. Play now →

Some links may be affiliate links. As an Amazon Associate, HempDollars earns from qualifying purchases.